Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 332 followers
Latest posts
Last updated 11 minutes ago
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
11 minutes ago
Galapagos took a 228 million euro ($269 million) hit last year as...
Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD
about 2 hours ago
Women’s-health-focused pharma Organon is grabbing exclusive global licensing rights to Sebela Pharmaceuticals’...
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
about 14 hours ago
Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global...
FDA illuminates new approval pathway for bespoke gene editing therapies
about 19 hours ago
After teasing a new regulatory process for personalized genetic medicines at the...
Angelini nocks an AI arrow with $120M Quiver Bioscience deal
about 20 hours ago
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver...
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
about 21 hours ago
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension...
Generate plans $425M IPO to bankroll antibody’s phase 3 asthma trials
about 21 hours ago
Generate:Biomedicines is hoping to raise up to $425 million via an IPO...
FDA issues safety alert on Trividia blood glucose monitors
about 23 hours ago
The FDA is flagging a high-risk issue with blood glucose monitors manufactured...
Gilead inks $7.8B Arcellx buyout to steer CAR-T into J&J showdown
about 23 hours ago
Gilead has struck a deal to buy Arcellx for $7.8 billion to...
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price
about 23 hours ago
Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s Zepbound in...
MoonLake’s phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
1 day ago
MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped...
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
4 days ago
Breaking ground: iRegene’s NouvNeu001 hits first U.S. dosing in Parkinson’s Phase IIa...